Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($2.77) EPS for the quarter, beating the consensus estimate of ($4.21) by $1.44, Zacks reports. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $35.12 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.
Karyopharm Therapeutics Stock Performance
Shares of KPTI traded down $0.12 on Friday, hitting $5.32. 35,974 shares of the stock traded hands, compared to its average volume of 82,243. The company has a market capitalization of $45.96 million, a PE ratio of -5.22 and a beta of 0.33. The business has a 50 day simple moving average of $5.37 and a 200 day simple moving average of $8.71. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $17.85.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $54.00 to $42.00 and set an "outperform" rating for the company in a research note on Tuesday. StockNews.com lowered Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday. Royal Bank of Canada decreased their target price on shares of Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating on the stock in a research note on Tuesday. HC Wainwright increased their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a research report on Wednesday, February 26th. Finally, Barclays upped their price objective on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the company an "overweight" rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $43.20.
View Our Latest Stock Analysis on Karyopharm Therapeutics
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Further Reading
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
